IR

Isofol announces that an investigator-initiated study of arfolitixorin has been published in BJC Reports

GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study, evaluating the effect of the drug candidate arfolitixorin at tissue level, has been published in the scientific journal BJC Reports. The information in the press release is intended for investors. Modelle is an investigator-initiated study […]

Isofol announces that an investigator-initiated study of arfolitixorin has been published in BJC Reports Read More »

Isofol provides an operational update during investor meeting

GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide an operational update during today’s investor meeting. The company will present its evidence platform that forms the basis for the upcoming clinical study with drug candidate arfolitixorin, the intended study design for the phase Ib/II study, as well an update

Isofol provides an operational update during investor meeting Read More »

Isofol appoints nomination committee ahead of the Annual General Meeting 2025

GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the members of the nomination committee for the Annual General Meeting 2025 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2024. The information

Isofol appoints nomination committee ahead of the Annual General Meeting 2025 Read More »

Isofol Medical AB (publ) publishes interim report, January–September 2024

GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July–September 2024 Net revenue amounted to kSEK 0 (0) and

Isofol Medical AB (publ) publishes interim report, January–September 2024 Read More »

Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025

GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that an abstract with results from a post hoc-analysis of the company’s Phase III-study AGENT has been accepted by ASCO GI, which takes place in San Francisco, US, between January 23-25th, 2025. The information in the press release is intended

Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025 Read More »

A Late Breaking Abstract concerning arfolitixorin will be presented at ENA 2024 today

GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract concerning the drug candidate arfolitixorin is presented as a poster at ENA 2024 in Barcelona, Spain, during October 23-25th 2024. The poster describes a dose-dependent cytotoxic effect and increased activity of arfolitixorin at higher doses

A Late Breaking Abstract concerning arfolitixorin will be presented at ENA 2024 today Read More »

Isofol announces that a Late Breaking Abstract has been accepted by ENA 2024

GOTHENBURG, SWEDEN, October 9, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract has been accepted for a poster presentation at ENA 2024, which will take place in Barcelona, Spain, during October 23-25th 2024. The information in the press release is intended for investors. The ENA 2024 EORTC-NCI-AACR’s

Isofol announces that a Late Breaking Abstract has been accepted by ENA 2024 Read More »

Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin

GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product patent application for arfolitixorin, submitted under the PCT (Patent Cooperation Treaty). If granted, the patent could significantly strengthen and prolong arfolitixorin’s intellectual property protection internationally. The information in

Isofol strengthens the outlook for further extending the patent protection of its drug candidate arfolitixorin Read More »

Isofol Medical AB (publ) publishes interim report, January–June 2024

GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2024 Net revenue amounted to kSEK 0 (0) and

Isofol Medical AB (publ) publishes interim report, January–June 2024 Read More »

Scroll to Top